COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (TNF) drugs or that the if there was a response, it is no longer present. The main question this study aims to answer is: Are the newer medications used to treat IBD just as safe and effective for treating IBD in children. Participants will already be taking these newer medications as assigned by their regular health care provider.Participants' care will be managed by their regular healthcare provider as part of usual (standard) care for those with PIBD. While taking these medications, participants will be asked to answer questions about their symptoms and health periodically over the course of the study.

NCT Number	NCT07198113
Lead Sponsor	University of North Carolina, Chapel Hill Collaborators: Patient-Centered Outcomes Research Institute, Duke Clinical Research Institute
Conditions	Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Enrollment	1,100 participants
Start Date	2025-11-01
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-17